EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-Life Efficacy of Palbociclib and Ribociclib in Advanced Breast Cancer

Tugay Avci iD, Mustafa Sahbazlar iD, Ferhat Ekinci iD, Atike Pinar Erdogan iD

Current Oncology · 2025

DOI: 10.3390/curroncol32030161 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, 2025. Verfasst von Tugay Avci und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Faculty of Medicine, Manisa Celal Bayar University, Manisa 45030, Turkey. Hauptthemen laut MEDLINE: Breast Neoplasms, Purines, Aminopyridines, Piperazines. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Clinical trials in metastatic hormone receptor-positive (HR+) human epidermal growth factor receptor-2 (HER2)-negative patients have shown that cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors both increase response rates and provide survival benefits. The efficacy of these therapies needs to be supported by real-life data. In this study, we aimed to evaluate treatment response, survival and affecting factors in patients with HR+/HER2− metastatic breast cancer (MBC) who were followed up with CDK 4/6 inhibitors in our center. Materials and methods: A retrospective analysis of 120 patients with HR+/HER2− MBC treated with ribociclib or palbociclib in combination with letrozole or fulvestrant was performed.

Results

Median progression-free survival (mPFS) was 24 months in the general population, 27 months in the ribociclib arm and 20 months in the palbociclib arm, with no significant difference in progression-free survival (PFS) in both arms (p = 0.25). The mPFS was longer in the ribociclib + letrozole arm compared to palbociclib + letrozole (27 vs. 20 months, respectively). PFS was also longer in patients receiving ribociclib + fulvestrant compared to palbociclib + fulvestrant but not statistically significant (33 vs. 21 months, respectively). Median overall survival (mOS) was not reached, but 3-year overall survival (OS) was statistically significantly longer in the ribociclib arm (87% vs. 55.5%, respectively, p = 0.03).

Conclusion

Palbociclib and ribociclib are first-line treatment options for metastatic HR+/HER2− disease and have similar efficacy. In our study, while the mPFS was not statistically significant in both arms, the 3-year OS rate was higher in the ribociclib arm and statistically significant. Our findings were confirmed in randomized studies comparing both agents head-to-head.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsPurinesAminopyridinesPiperazinesPyridinesAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMiddle AgedRetrospective StudiesAgedAdultAged, 80 and overLetrozole

Stichwörter der Autor:innen

CDK 4/6 inhibitorsfulvestrantletrozolmetastatic breast cancerpalbociclibribociclib

Substanzen

ribociclibPurinespalbociclibAminopyridinesPiperazinesPyridinesLetrozole

Autor:innen und Institutionen

  • Department of Medical Oncology, Faculty of Medicine, Manisa Celal Bayar University, Manisa 45030, Turkey.

ORCID-Profile: Tugay Avci, Mustafa Sahbazlar, Ferhat Ekinci, Atike Pinar Erdogan

Zitieren

APA

Avci, T., Sahbazlar, M., Ekinci, F., & Erdogan, A. P. (2025). Real-Life Efficacy of Palbociclib and Ribociclib in Advanced Breast Cancer. Current Oncology. https://doi.org/10.3390/curroncol32030161

Vancouver

Avci T, Sahbazlar M, Ekinci F, Erdogan AP. Real-Life Efficacy of Palbociclib and Ribociclib in Advanced Breast Cancer. Current Oncology. 2025. doi:10.3390/curroncol32030161

BibTeX
@article{Avci2025,
  author = {Avci, Tugay and Sahbazlar, Mustafa and Ekinci, Ferhat and Erdogan, Atike Pinar},
  title = {Real-Life Efficacy of Palbociclib and Ribociclib in Advanced Breast Cancer},
  journal = {Current Oncology},
  year = {2025},
  doi = {10.3390/curroncol32030161}
}
Kostenlos starten →